Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-Linker Conjugates for ADC
Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan is a specialized drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features an Exatecan cytotoxin, which targets and inhibits DNA topoisomerase I, leading to apoptotic cell death in cancer cells. It is ideal for research in targeted cancer therapies, enhancing the effectiveness of ADCs while minimizing systemic toxicity. -
Drug-Linker Conjugates for ADC
Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound comprises the cytotoxic agent Hydrotecan and a peptide linker featuring L-Ala, L-Val, and L-Gln residues. It is utilized in research focused on targeted cancer therapies, facilitating the selective delivery of cytotoxic agents to tumor cells while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan serves as a drug-linker conjugate utilized in antibody-drug conjugate (ADC) applications. This compound demonstrates significant potential in targeted cancer therapy, allowing for the selective delivery of cytotoxic agents to tumoral cells. Its design facilitates efficient drug release upon internalization, enhancing therapeutic efficacy while minimizing systemic exposure. Researchers can explore its utility in developing novel ADC formulations for improved treatment strategies. -
Drug-Linker Conjugate for ADC
Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker (Aminocaproyl-Val-Cit-PABC) linked to Exatecan, a potent topoisomerase I inhibitor. It is suitable for synthesizing ADC molecules, facilitating targeted cancer therapies by delivering cytotoxic agents directly to cancer cells while minimizing effects on normal tissues. -
Drug-Linker Conjugates for ADC
Mc-Pro-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound comprises Monomethyl auristatin E (MMAE) conjugated through a proprietary linker, enabling targeted delivery of cytotoxic agents to tumor cells. Mc-Pro-PAB-MMAE is suitable for the synthesis of ADCs, allowing researchers to explore novel therapeutic strategies in cancer treatment. -
Drug-Linker Conjugates for ADC
VcMMAE-Eribulin is a targeted drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent microtubule inhibitors MMAE and Eribulin. This compound facilitates the selective delivery of cytotoxic agents to cancer cells, enhancing the therapeutic efficacy while minimizing off-target effects. VcMMAE-Eribulin is essential for synthesizing ADCs aimed at targeted cancer treatments, making it a valuable tool in oncological research. -
Drug-Linker Conjugates for ADC
Val-Ala-PABC-Exatecan trifluoroacetate is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises a cleavable Val-Ala-PABC linker and Exatecan, a potent topoisomerase I inhibitor. This reagent enables the synthesis of ADC molecules by facilitating targeted delivery and controlled release of the cytotoxic agent, making it suitable for advancing cancer research and therapeutic development. -
Drug-Linker Conjugate for ADC
MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It integrates Exatecan, a potent inhibitor of DNA Topoisomerase I, with an IC50 value of 2.2 μM. This conjugate enables targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. It is suitable for research involving ADC development and optimization in cancer therapeutics. -
Drug-Linker Conjugate for ADC
2-MSP-5-HA-VA-PAB-Exatecan is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound incorporates Exatecan, a potent topoisomerase I inhibitor, linked via a stable spacer. It is utilized in the synthesis of ADCs, enabling targeted delivery of cytotoxic agents to cancer cells, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugates For ADC
Aminobenzenesulfonic auristatin E is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound exhibits potent antitumor activity through its mechanism as a cytotoxic tubulin modifier, utilizing Auristatin E linked via the aminobenzenesulfonic linker. It is valuable for research focused on enhancing targeted cancer therapies by improving the efficacy and selectivity of therapeutic agents. -
Drug-Linker Conjugate for ADC
mp-dLAE-PABC-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound incorporates Monomethyl auristatin E, a potent tubulin inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in target cells. It is particularly valuable in cancer research and therapeutic applications, enabling the targeted delivery of cytotoxic agents to enhance treatment efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
LNK2-S is a drug-linker conjugate designed for the synthesis of antibody-drug conjugates (ADCs). This compound features the toxin molecule Exatecan, enabling targeted delivery of cytotoxic agents to cancer cells. LNK2-S is suitable for research applications focused on ADC development, enhancing therapeutic efficacy while minimizing off-target effects. -
ADC Linker-payload
Exatecan-mpGNNG is a linker-payload component designed for use in antibody-drug conjugates (ADCs). It integrates Exatecan, a highly effective inhibitor of topoisomerase I, facilitating targeted delivery of therapeutic agents to cancer cells. This compound is particularly relevant for research applications focusing on ADC development and the evaluation of antitumor efficacy. -
Drug-Linker Conjugate for ADC
LP-6 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. It features an Eg5 inhibitor that effectively targets mitotic kinesins, providing potent anti-cancer activity. This compound is crucial for developing ADCs aimed at precise and targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
Lys-Nε-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the potent tubulin inhibitor DM4 with the Lys-Nε-SPDB linker to facilitate targeted delivery and enhanced therapeutic efficacy. Lys-Nε-SPDB-DM4 is suitable for research focused on cancer therapeutics, particularly in studies investigating the mechanisms of action and optimization of ADCs. -
MMAF-ADC Linker
Fmoc-Val-Cit-PAB-MMAF-OtBu is a linker compound designed for the conjugation of MMAF (monomethyl auristatin F) to antibodies, facilitating the formation of antibody-drug conjugates (ADCs). This versatile linker allows for the selective delivery of the cytotoxic agent to tumor cells, enhancing anti-tumor efficacy while minimizing systemic toxicity. Fmoc-Val-Cit-PAB-MMAF-OtBu is suitable for research applications in ADC development and cancer therapeutics. -
Drug-Linker Conjugates for ADC
MC-VC-PAB-Daptomycin is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It comprises Daptomycin, a lipopeptide antibiotic known for its potent antibacterial activity, linked through a specialized polymeric bridge. This conjugate facilitates targeted delivery of therapeutic agents, enhancing the efficacy of ADCs in treating various cancers and bacterial infections. Its unique structure allows for selective action while minimizing off-target effects, making it a valuable tool in drug development and research applications. -
Drug-Linker Conjugate for ADC
Val-Ala-PAB-SN38 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, combining the Val-Ala-PAB linker with SN38, the active metabolite of the Topoisomerase I inhibitor Irinotecan. This compound is engineered to facilitate targeted delivery of chemotherapy, enhancing the efficacy and specificity of cancer treatment. It is useful for research focused on ADC development and the investigation of Topoisomerase I inhibition in cancer therapy. -
Drug-Linker Conjugates for ADCs
Boc-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a Boc-Val-Cit-PAB linker connected to the microtubule inhibitor MMAE, facilitating targeted delivery of cytotoxic agents to cancer cells. Boc-Val-Cit-PAB-MMAE is suitable for the synthesis of ADCs, enhancing therapeutic efficacy while minimizing off-target effects in cancer research. -
Drug-Linker Conjugates for ADC
DL-01 is a drug-linker conjugate specifically designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing systemic toxicity. DL-01 is essential for research applications focusing on ADC development and optimization in cancer therapy. -
Drug-Linker Conjugate for ADC
Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This reagent facilitates targeted delivery of the potent antitumor antibiotic Duocarmycin SA through its unique linker structure, Mal-PEG4-VC-PAB-DMEA-Seco. Its primary mechanism involves the selective release of the cytotoxic agent upon cellular internalization, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is suitable for cancer research focused on developing and optimizing ADCs for improved clinical outcomes. -
Drug-Linker Conjugate for ADC
Aminocaproyl-Val-Cit-PABC-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, combining a cleavable linker (Aminocaproyl-Val-Cit-PABC) with Exatecan, a potent topoisomerase I inhibitor. This compound facilitates targeted cytotoxic activity, which is crucial for the development of effective ADCs. It is suitable for research aimed at enhancing the efficacy and specificity of cancer therapies through ADC synthesis. -
Drug-linker Conjugate for ADC
DBCO-PEG3-Glu-VC-PABC-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features the tubulin inhibitor MMAF linked through a cathepsin cleavable DBCO-PEG3-Glu-VC-PABC moiety, facilitating targeted delivery of the cytotoxic agent. This compound is valuable for research applications focusing on the development of ADCs, enabling studies on efficacy, mechanism of action, and therapeutic potential in cancer treatment. -
Drug-Linker Conjugates for ADC
AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features the natural bis-intercalator SW-163D linked through the AcLysValCitPABC-DMAE moiety, facilitating targeted delivery of cytotoxic agents. It is instrumental in enhancing the efficacy of ADCs by improving specificity and reducing off-target effects in cancer research applications. -
ADC Linker
Fmoc-Phe-Lys(Trt)-PAB-PNP is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies while allowing for selective release in the target environment. Its design enables enhanced efficacy in targeted cancer therapy, making it a valuable tool for researchers developing ADCs. -
ADC linker
Aminoxyacetamide-PEG3-azide is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis, targeting efficient conjugation in bioconjugation applications. This reagent features an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and is also suitable for strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups. Its versatile click chemistry capabilities make it an essential tool in the development of targeted therapeutics. -
ADC Linker
DBCO-PEG3-TCO is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs), featuring a 3-unit polyethylene glycol (PEG) spacer. This reagent facilitates click chemistry through its dibenzocyclooctyne (DBCO) moiety, enabling strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-functionalized compounds. Additionally, the TCO group supports inverse electron demand Diels-Alder (iEDDA) reactions with tetrazine-containing molecules, making DBCO-PEG3-TCO a versatile tool for advancing ADC development in therapeutic research. -
ADC Linker
m-PEG11-Amine is a cleavable linker designed for the functionalization of antibody-drug conjugates (ADCs). This polyethylene glycol (PEG)-based compound enhances solubility and stability of ADCs, facilitating targeted delivery of cytotoxic agents. In addition to its application in ADCs, m-PEG11-Amine is also suitable for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation research. -
ADC Linker
(2R,4R)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate functions as a non-cleavable linker for antibody-drug conjugates (ADCs), facilitating the formation of stable conjugates for targeted cancer therapies. This compound serves as an effective alkyl chain-based PROTAC linker, allowing for the development of proteolysis-targeting chimeras that can induce selective degradation of specific proteins in research studies. Its robust mechanism makes it a valuable tool in the fields of drug development and targeted therapy. -
ADC Linker
Mal-PEG2-Val-Cit-PAB-OH is a cleavable linker specifically designed for use in antibody-drug conjugates (ADCs). This compound enables controlled release of therapeutic agents, enhancing the efficacy and safety of ADC formulations. Additionally, it serves as a versatile PROTAC linker, facilitating the synthesis of proteolysis-targeting chimeras for targeted protein degradation research. -
ADC Linker
4-Methyl-4-(methyldisulfanyl)pentanoic acid is a cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). Its unique disulfide bond enables selective release of therapeutic agents upon internalization by target cells, enhancing the efficacy of ADCs in cancer therapy. This compound is crucial for researchers developing novel ADC formulations aimed at improving targeted delivery and reducing systemic side effects. -
ADC/PROTAC Linker
DBCO-NHCO-PEG4-NH-Boc is a versatile PROTAC linker featuring a cleavable structure designed for the synthesis of PROTACs and antibody-drug conjugates (ADCs). This compound utilizes a DBCO moiety, enabling efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its PEG4 spacer enhances solubility and stability, making it suitable for various biological applications in drug development and therapeutic research. -
ADC Linker
SMPT is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates stable attachment between antibodies and cytotoxic drugs, ensuring targeted delivery without premature release. This linker is essential for enhancing the therapeutic efficacy of ADCs in cancer research and development. -
ADC Linker
Methyl 1-Cbz-azetidine-3-carboxylate is a non-cleavable linker utilized in the development of antibody-drug conjugates (ADCs). This compound can also serve as an alkyl chain-based PROTAC linker, facilitating the synthesis of PROTACs for targeted protein degradation studies. Its unique structure provides robust stability and effective conjugation capabilities, making it an essential reagent for advanced therapeutic research and development. -
ADC Linker
m-PEG6-CH2CH2CHO is a PEG-based non-cleavable linker employed in the development of antibody-drug conjugates (ADCs). This compound facilitates stable conjugation between antibodies and therapeutic agents, ensuring effective targeting and delivery of antivirals or chemotherapeutics. Additionally, m-PEG6-CH2CH2CHO can also serve as a linker in the synthesis of PROTACs, contributing to targeted protein degradation research applications. -
ADC Linker
Azidoethyl-SS-ethylamine is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, Azidoethyl-SS-ethylamine is capable of undergoing strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN groups, making it a versatile tool for bioconjugation applications in chemical biology and pharmacology research. -
ADC/PROTAC Linker
DBCO-NHCO-PEG4-amine is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and PROTACs. This cleavable linker facilitates the conjugation of payloads such as MMAE to antibodies, enhancing targeted delivery to cancer cells. It has demonstrated compelling biological activities, with EC50 values of 280 nM and 22 nM for DBCO-VCpAB MMAE and DBCO-TRX MMAE, respectively, in SKBR3 cells, making it a valuable tool for researchers investigating targeted therapies. -
ADC Linker
Mc-d-Val-d-Cit-PAB-PNP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to specific cells, enhancing therapeutic efficacy while minimizing systemic toxicity. It is particularly valuable in studies focused on ADC development and optimization in cancer research. -
ADC Linker
MCC is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). By forming stable covalent bonds between antibodies and cytotoxic drugs, MCC enhances the therapeutic efficacy of ADCs. This compound is widely utilized in research aimed at developing targeted cancer therapies, ensuring localized delivery of potent agents while minimizing systemic toxicity. -
ADC linker
NHPI-PEG2-C2-NHS ester is a non-cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This 2-unit PEG linker provides increased stability and solubility, facilitating the delivery of cytotoxic agents to targeted cells. Its application in ADC development enhances therapeutic efficacy and minimizes off-target effects, making it a valuable reagent for cancer research and drug formulation studies. -
ADC Linker
Ac-EEVC-OH is a linker designed for antibody-drug conjugate (ADC) synthesis. This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing targeted delivery and efficacy in cancer therapy. Its application in ADC development supports research aimed at improving therapeutic outcomes and minimizing off-target effects. -
ADC Linker
Mal-amide-PEG4-Val-Cit-PAB-OH is a cleavable linker featuring a Maleimide group, primarily used in the synthesis of antibody-drug conjugates (ADCs). This linker facilitates the conjugation of therapeutic agents to antibodies, ensuring targeted delivery in cancer research and therapeutic applications. Its design allows for precise cleavage in the tumor environment, enhancing the efficacy and reducing off-target effects of ADCs. -
ADC/PROTAC Linker
Tr-PEG3-OH is a non-cleavable linker comprised of a three-unit polyethylene glycol (PEG) chain, designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound enhances the solubility and stability of ADCs, facilitating targeted delivery of cytotoxic agents to specific cells. Its applications extend to PROTAC (proteolysis-targeting chimera) technology, enabling the development of innovative therapies that harness targeted protein degradation. -
ADC/PROTAC Linker
Propargyl-PEG7-acid is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). It features a propargylic group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling effective conjugation to azide-containing molecules. This compound serves as a cleavable linker, providing versatility in drug delivery systems and targeted therapy research. Propargyl-PEG7-acid is essential for studies focusing on the development of innovative therapeutic modalities through advanced chemical synthesis techniques. -
Non-Cleavable ADC Linker
(2R,4S)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid acts as a non-cleavable linker for antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of therapeutic agents to antibodies, enhancing targeted delivery in cancer research. Additionally, it serves as an alkyl chain-based linker in the development of PROTACs, supporting studies in targeted protein degradation. -
ADC Linker
Mal-PEG4-PFP ester is a non-cleavable ADC linker featuring a maleimide moiety, a polyethylene glycol (PEG) chain of four units, and a PFP ester. This linker facilitates the stable conjugation of antibody-drug pairs, enhancing the efficacy and specificity of targeted therapies. It is especially useful in the development of antibody-drug conjugates (ADCs) for cancer treatment and other therapeutic applications, allowing for improved delivery of cytotoxic agents to tumor cells. -
ADC Linker
N-Boc-4-hydroxy-L-proline methyl ester serves as a non-cleavable linker for antibody-drug conjugates (ADCs), facilitating the targeted delivery of therapeutic agents. This compound also functions as an alkyl chain-based linker in the synthesis of PROTACs (proteolysis-targeting chimeras), contributing to the modulation of protein degradation pathways. Its utility in both ADC and PROTAC applications makes it valuable for advancing research in targeted therapies and protein regulation. -
ADC Linker
Hydroxy-PEG2-(CH2)2-Boc is an uncleavable linker specifically designed for use in antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of therapeutic agents to antibodies, enhancing delivery and efficacy in targeted cancer therapies. Additionally, Hydroxy-PEG2-(CH2)2-Boc serves as a suitable linker for the synthesis of PROTACs, aiding in the development of targeted protein degradation applications. -
ADC Linker
SC209 intermediate-1 is an advanced antibody-drug conjugate (ADC) linker designed to facilitate the synthesis of ADCs. Its efficient coupling properties enable the attachment of cytotoxic agents to antibodies, enhancing targeted delivery for cancer therapy. This compound is essential for researchers developing novel ADC formulations aimed at improving therapeutic efficacy and minimizing off-target effects. -
ADC Linker
BCN-exo-PEG3-maleimide is an ADC linker featuring three PEG units and a bidentate macrocyclic ligand, BCN. It facilitates the formation of stable triazole structures through click chemistry with azide-containing molecules, eliminating the need for catalysts. The maleimide moiety is designed to degrade in aqueous conditions, making it suitable for various drug delivery applications and enhancing the efficacy of antibody-drug conjugates (ADCs) in targeted therapy research.
